Delving into the Latest Updates on Shanghai Keqi Pharmaceutical Technology Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Shanghai Ultra-T Immune Therapeutics is a wholly-owned subsidiary of Novatim Immune Therapeutics (Zhejiang) Co., Ltd. It was established on November 11, 2018, and is located in Shanghai, China. The company is a biopharmaceutical technology enterprise specializing in the research and clinical application of innovative drugs in the field of tumor immunotherapy. Ultra-T Immune Therapeutics primarily focuses on the research and clinical application of CAR-T cell immunotherapy. With a deep involvement in precision immunotherapy since 2013, the company has established a comprehensive research and production platform covering antibody screening to CAR-T preparation. The company places a significant emphasis on developing highly original therapeutic products. Currently, Ultra-T Immune Therapeutics has obtained multiple patents, including inventions such as a TM4SF1-specific chimeric antigen receptor and its application, a monomeric antibody against BCMA and its application, and a chimeric antigen receptor targeting EpCAM and its application.

Tags

Neoplasms

Fusion protein

Bispecific antibody

Autologous CAR-T

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3

Top 5 Drug Type	Count

Bispecific antibody	1
Autologous CAR-T	1
Fusion protein	1

Top 5 Target	Count

TM4SF1(transmembrane 4 L six family member 1)	1
IL-2 x PD-1	1
CD19(B-lymphocyte antigen CD19)	1

I期研究（剂量递增研究）：主要目的: (1)评价KQ-2003 CAR-T细胞在R/R MM患者的安全性、耐受性，并确定最大耐受剂量(MTD)、剂量限制性毒性(DLT)和II期推荐剂量(RP2D); (2)考察KQ-2003 CAR-T细胞在R/R MM患者体内的药代动力学(PK)/药效动力学(PD)特征及免疫原性。次要目的: 评价KQ-2003 CAR-T细胞在R/R MM患者的初步有效性。 IIa期研究(队列扩展研究): 主要目的: 评价KQ-2003 CAR-T细胞RP2D在R/R MM患者的安全性、耐受性和初步有效性；次要目的: 考察KQ-2003 CAR-T细胞在R/R MM患者体内的PK/PD特征及免疫原性。

[Translation]

Phase I study (dose escalation study): Primary objectives: (1) To evaluate the safety and tolerability of KQ-2003 CAR-T cells in R/R MM patients, and determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and phase II recommended dose (RP2D); (2) To investigate the pharmacokinetic (PK)/pharmacodynamic (PD) characteristics and immunogenicity of KQ-2003 CAR-T cells in R/R MM patients. Secondary objectives: To evaluate the preliminary efficacy of KQ-2003 CAR-T cells in R/R MM patients. Phase IIa study (cohort expansion study): Primary objectives: To evaluate the safety, tolerability and preliminary efficacy of KQ-2003 CAR-T cells RP2D in R/R MM patients; Secondary objectives: To investigate the PK/PD characteristics and immunogenicity of KQ-2003 CAR-T cells in R/R MM patients.

Start Date31 Oct 2023

Sponsor / Collaborator

Shanghai Keqi Pharmaceutical Technology Co., Ltd.

NCT05673434 / Not yet recruitingNot ApplicableIIT

A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1-positive Tumors of Digestive System

Transmembrane 4 L Six Family Member 1 (TM4SF1) is highly expressed in many tumors of digestive system .
The Chimeric Antigen Receptor T-cells (CAR-T) that target TM4SF1 has been generated in our good manufacturing practices (GMP) facility and the anti-tumor effects have been demonstrated in multiple in vitro and in vivo studies.
Clinical studies are proposed here to evaluate the anti-tumor activity of these cell therapy products for treatment of patients with TM4SF1 positive tumors of digestive system. In this study, the safety, tolerance, and preliminary efficacy of CART-TM4SF1 cells will be examined in patients with refractory/recurrent advanced pancreatic cancer, colorectal cancer, gastric cancer or liver cancer.
Clinical and immunological responses will be evaluated about 30 days and last up to 2 years after CAR-T cell infusion.

Start Date30 Jan 2023

Sponsor / Collaborator

Shanghai Changhai Hospital

[+1]

NCT04714593 / Unknown statusPhase 1/2IIT

A Clinical Study to Evaluate the Safety and Effectiveness of CD19- BCMA CAR - T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia

Evaluation the safety,tolerability, preliminary efficacy,and PK/PD of CD19-CD22 CAR-T cells for the treatment of acute B lymphocytic leukemia.

Start Date15 Jan 2021

Sponsor / Collaborator

Shanxi Province Cancer Hospital

[+1]

100 Clinical Results associated with Shanghai Keqi Pharmaceutical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Keqi Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Keqi Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Keqi Pharmaceutical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

1

IND Application

Login to view more data